Chiesi Group, a biopharmaceutical company, has rolled out the Impulse platform to boost partnership and patient care.
The Impulse platform is designed to accelerate ideas and foster meaningful partnerships in healthcare.
It focuses on addressing challenges for patients, the planet, and communities. It goes beyond treating symptoms, and tackling root causes like climate change and access to care.
The Impulse is also intended to meet the rising demand for healthcare solutions that meet patient needs.
It provides a collaborative space for researchers, start-ups, and innovators to work together.
In addition, this platform drives advancements in digital health and sustainable patient care models. These solutions can help in healthcare delivery and patient care.
Chiesi Group center of open innovation & competence vice-president Fabrizio Conicella said: “We stand at a pivotal moment for the pharmaceutical industry. This is the time to further rethink traditional models and embrace bolder, patient-centric innovation.
“That’s why Chiesi has created The Impulse, aiming to empower those who are driven by a passion to improve the lives of others through innovation.
“We know that some of the most groundbreaking ideas come from collaboration. By providing the resources, network, and support, we aim to accelerate ideas that will have a tangible impact on patients and the world around us, perfectly in line with our Company vision.”
The launch of the Impulse will help replace traditional care models. It will also help develop solutions that enhance patient outcomes while promoting a healthier planet.
The platform has already garnered interest from firms in life sciences, digital health, and environmental sustainability, including Karolinska Institutet, NOME, and EIT-HEALTH. Other partnerships are in development.
In February this year, Chiesi Global Rare Diseases, a division of Chiesi Group, received Health Canada’s approval for Myalepta (metreleptin for injection). This treatment is designed for patients with lipodystrophy (LD).
